ROS-MS
What it found
No result yet.
What was tested
Treatment tested
- Blood samples for PK
What it measured
Main measures
Serum drug concentration measured using liquid chromatography tandem mass spectrometry (LC-MS/MS)
Up to 24 weeks (during one cycle of treatment, injection of rituximab or ocrelizumab is scheduled every 6 months)
How the body handles the medicine
Who could take part
Relapsing MS · 18 to 60
Inclusion Criteria: * Included in OVERLORD-MS (NCT04578639) * Willing to attend laboratory for blood sample collection at scheduled time points Exclusion criteria: * Not willing to attend laboratory for blood sample collection at scheduled time points
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Papers
Loading reviews and guidelines…
Linked trials
Refers to
OVERLORD-MSPhase 3 · Running, not recruiting
Links found where a registry record names another trial's registry number.
History
Started
Mar 2021
Main results due
Dec 2025
Finished
Dec 2027
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error